Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | SMO | Q99835 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29436267 | 1.00 | MAPT (0.49) | MAPTKMT2AMEN1CNR1KDM4E | |
| SCHEMBL12643198 | 0.93 | KMT2A (0.49) | MAPTKMT2AMEN1CNR1KDM4E | |
| SCHEMBL14668252 | 0.91 | TP53 (0.53) | MAPTKMT2AMEN1CNR1KDM4E | |
| SCHEMBL17636193 | 0.87 | GAA (0.53) | SMOALDH1A1NPC1SLC6A9 | |
| SCHEMBL30511079 | 0.87 | GAA (0.53) | SMOALDH1A1NPC1SLC6A9 | |
| SCHEMBL32672556 | 0.86 | SMO (0.44) | SMONPC1SLC6A9 | |
| SCHEMBL32672541 | 0.84 | SLC6A9 (0.44) | SMOTP53SLC6A9 | |
| SCHEMBL32672593 | 0.83 | SMO (0.47) | KMT2AMEN1SMOTP53ALDH1A1 | |
| SCHEMBL32672552 | 0.82 | SMO (0.47) | MAPTKMT2AMEN1SMOTP53 | |
| SCHEMBL16270375 | 0.81 | SLC6A9 (0.39) | SMONPC1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117412668-A | Livestock in vitro breeding system and method | ABS全球公司 | 2024-01-16 | — | — | CN | disclosed |
| US-20230346847-A1 | JUVENILE PROTECTIVE FACTORS TO ARREST AND REVERSE AGING IN THE ENTERIC NERVOUS SYSTEM | THE JOHNS HOPKINS UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| US-20230346847-A1 | JUVENILE PROTECTIVE FACTORS TO ARREST AND REVERSE AGING IN THE ENTERIC NERVOUS SYSTEM | THE JOHNS HOPKINS UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| US-20210244728-A1 | Method of treating peripheral neuropathy | CHEMEDEST LTD (EE) | 2021-08-12 | — | — | US | disclosed |
| US-20200113895-A1 | Method of treating peripheral neuropathy | CHEMEDEST LTD. (EE) | 2020-04-16 | — | — | US | disclosed |
| US-20180036305-A1 | Method of treating peripheral neuropathy | CHEMEDEST LTD. (EE) | 2018-02-08 | — | — | US | disclosed |
| US-20180036305-A1 | Method of treating peripheral neuropathy | CHEMEDEST LTD. (EE) | 2018-02-08 | — | — | US | disclosed |
| US-20160136159-A1 | Method for Treating Peripheral Neuropathy | CHEMEDEST LTD. (EE) | 2016-05-19 | — | — | US | disclosed |
| US-20160136159-A1 | Method for Treating Peripheral Neuropathy | CHEMEDEST LTD. (EE) | 2016-05-19 | — | — | US | disclosed |
| EP-2509953-B1 | METHODS OF FACILITATING NEURAL CELL SURVIVAL USING GDNF FAMILY LIGAND (GFL) MIMETICS OR RET SIGNALING PATHWAY ACTIVATORS | GENECODE AS (EE) | 2016-03-30 | — | — | EP | disclosed |
| US-8901129-B2 | Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators | GENECODE AS (EE) | 2014-12-02 | — | — | US | disclosed |
| US-8901129-B2 | Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators | GENECODE AS (EE) | 2014-12-02 | — | — | US | disclosed |
| US-20130030180-A1 | Methods of Facilitating Neural Cell Survival Using GDNF Family Ligand (GFL) Mimetics or RET Signaling Pathway Activators | GENECODE AS (EE) | 2013-01-31 | — | — | US | disclosed |
| US-20130030180-A1 | Methods of Facilitating Neural Cell Survival Using GDNF Family Ligand (GFL) Mimetics or RET Signaling Pathway Activators | GENECODE AS (EE) | 2013-01-31 | — | — | US | disclosed |
| WO-2011070177-A2 | METHODS OF FACILITATING NEURAL CELL SURVIVAL USING GDNF FAMILY LIGAND (GFL) MIMETICS OR RET SIGNALING PATHWAY ACTIVATORS | BALTIC TECHNOLOGY DEVELOPMENT, LTD. (EE) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136159-A1 | Method for Treating Peripheral Neuropathy | GFRA3, GAP43, GFRA2 | MAPT 2102/4885KMT2A 4658/4885MEN1 3210/4885 |
| US-20210244728-A1 | Method of treating peripheral neuropathy | GFRA3, GFRA2, GFRA1 | MAPT 2913/4885KMT2A 4737/4885MEN1 4272/4885 |
| US-20180036305-A1 | Method of treating peripheral neuropathy | GFRA3, GFRA2, GAP43 | MAPT 1931/4885KMT2A 4717/4885MEN1 3534/4885 |
| US-20130030180-A1 | Methods of Facilitating Neural Cell Survival Using GDNF Family Ligand (GFL) Mimetics or RET Signaling Pathway Activators | GFRA2, GFRA1, GFRA3 | MAPT 1067/4885KMT2A 3096/4885MEN1 2744/4885 |
| US-20230346847-A1 | JUVENILE PROTECTIVE FACTORS TO ARREST AND REVERSE AGING IN THE ENTERIC NERVOUS SYSTEM | FABP2, GAP43, CHAT | MAPT 1509/4885KMT2A 3800/4885MEN1 3962/4885 |
| US-20200113895-A1 | Method of treating peripheral neuropathy | GFRA3, GFRA1, GFRA2 | MAPT 2637/4885KMT2A 4770/4885MEN1 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.